The purpose of the report is to illustrate the state of the market of Glioblastoma Multiforme, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report with Toc: https://www.credenceresearch.com/report/glioblastoma-multiforme-market
Glioblastoma multiforme (GBM) belongs to a group of brain tumors known as gliomas that grows from a type of brain cell called a glial cell. It is the most common primary brain tumor in adults and also the most aggressive form of brain tumor. According to U.S. National Cancer Institute, GBM is considered as the most aggressive form of brain cancer which represents 15.4% of all primary brain tumors and about 60% – 75% of all astrocytoma and shows rapid growth rate of benign cells in the organ. According to World Health Organization (WHO), the incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. Overall GBM accounts for 12 to 15% of all intracranial tumors and 50 to 60% of astrocytic tumors. In year 2015, temozolomide accounted for the largest market share of the global glioblastoma multiforme market. The key advantages possessed by temozolomide are delayed progression without impacting the quality of life and less adverse effects compared to other molecules. Medical practitioners suggest that, combination radiotherapy and temozolomide chemotherapy is currently the standard of care for most patients suffering from GBM.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Glioblastoma Multiforme buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Glioblastoma Multiforme contains:
Analysis and forecast of Glioblastoma Multiforme market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Glioblastoma Multiforme market;
Assessment and forecast of Glioblastoma Multiforme market development;
Financial and business profiles of the leading companies in the Glioblastoma Multiforme industry.
Also you can request us for sample in PDF with depth details and graph: https://www.credenceresearch.com/sample-request/57903
– Up to date working Glioblastoma Multiforme data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Glioblastoma Multiforme for the period 2018 to 2026
– Planned Glioblastoma Multiforme additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Glioblastoma Multiforme projects by region, key countries, and companies
– Details of major planned Glioblastoma Multiforme projects in the world up to 2026
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290